CClinicalTrials.gg
RecruitingNCT07431749Updated Aug 24, 2026

The Use of Dual-coil Transcranial Magnetic Stimulation to Measure and Modulate Poststroke Interhemispheric Inhibition.

An interventional study of Dual coil transcranial magnetic stimulation in Cortico-cortical Paired Associative Stimulation, sponsored by The Hong Kong Polytechnic University. Recruiting at 2 sites in Hong Kong. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Objectives: This project will (1) establish the test-retest reliability of a novel transcranial magnetic stimulation-electroencephalography (TMS-EEG) interhemispheric inhibition (IHI) measure and (2) validate it against the TMS-EMG-based IHI measure (the gold standard). It will also (3) compare effects of dual-coil cortico-cortical paired associative stimulation (ccPAS) protocols with different interstimulus intervals (ISI) on this TMS-EEG-based IHI marker in poststroke patients. Methods: Study 1: IHI will be conducted in 20 stroke patients and 20 healthy counterparts using TMS-EEG and TMS-EMG; furthermore, both measures will be repeated after one week for test-retest reliability. Study 2: A randomized-crossover trial where 20 stroke patients undergo a single-session ccPAS in three separate visits (ISI: 8ms: LTD-like, 12ms: LTP-like, 100ms: sham) to investigate the differential modulatory effects in IHI.

Read the detailed description

Objectives: This project will (1) establish the test-retest reliability of a novel transcranial magnetic stimulation-electroencephalography (TMS-EEG) interhemispheric inhibition (IHI) measure and (2) validate it against the TMS-EMG-based IHI measure (the gold standard). It will also (3) compare effects of dual-coil cortico-cortical paired associative stimulation (ccPAS) protocols with different interstimulus intervals (ISI) on this TMS-EEG-based IHI marker in poststroke patients. Methods: Study 1: IHI will be conducted in 20 stroke patients and 20 healthy counterparts using TMS-EEG and TMS-EMG; furthermore, both measures will be repeated after one week for test-retest reliability. Study 2: A randomized-crossover trial where 20 stroke patients undergo a single-session ccPAS in three separate visits (ISI: 8ms: LTD-like, 12ms: LTP-like, 100ms: sham) to investigate the differential modulatory effects in IHI.

02

Conditions studied

  • Cortico-cortical Paired Associative Stimulation

Browse trials for

Keywords

  • cortico-cortical paired associative stimulation
  • transcranial magnetic stimulation
  • stroke
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 659 studies on the registry; 250 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • (1) have a diagnosis of ischemic or hemorrhagic stroke, with time after stroke onset≥6 months. For stroke patients, we will invite participants to receive a structural magnetic resonance imaging (MRI) at the University Research Facility in Behavioral and Systems Neuroscience to verify their actual lesion location; (2) aged between 18 and 80 years old; (3) with residual upper limb functions from 4-7 levels in the Functional Test for the Hemiplegic Upper Extremity (Hong Kong version); (4) have evocable MEP from both M1; (5) able to give informed written consent to participate in the study. (6) able to understand and communicate with Chinese.

Exclusion criteria

Exclusion Criteria:

(1) any contraindications to TMS (screened by the safety checklist by Rossi); (2) any concomitant neurological disease; (3) any sign of moderate-to-severe cognitive problems, i.e., the abbreviated mental test Hong Kong version\<6 out of 10 points [22]; and (4) Modified Ashworth score>2 in hand, wrist or elbow extensor muscle in their hemiparetic upper limbs.

In addition, a group of right-hand-dominant healthy adults, without any known neurological and psychiatric diseases, will be enrolled.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ccPAS (8ms)

    ccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 8ms after the first pulse over the contralesional M1, during premovement stage.

    Device: Dual coil transcranial magnetic stimulation

  • Experimental
    ccPAS (12ms)

    ccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 12ms after the first pulse over the contralesional M1, during premovement stage.

    Device: Dual coil transcranial magnetic stimulation

  • Sham comparator
    Sham ccPAS

    ccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 100ms after the first pulse over the contralesional M1, during premovement stage.

    Device: Dual coil transcranial magnetic stimulation

Interventions

  • DeviceDual coil transcranial magnetic stimulation

    The ccPAS will be applied using a MagPro X100/R30 stimulator and a MagPro R20/R30 extension connected to two vertically oriented figure-of-eight coils designed for bilateral hemispheric stimulation.

06

What researchers measure

Primary outcomes

  1. transcranial magnetic stimulation-evoked potential in electroencephalography (TMS-EEG)

    The amplitude of P30 (28-35ms) will be extracted from the artifact-free TEP trials to represent the cortical excitatory activity.

    Time frame: Baseline

  2. Transcranial magnetic stimulation-evoked potential in electroencephalography

    The amplitude of P30 (28-35ms) will be extracted from the artifact-free TEP trials to represent the cortical excitatory activity.

    Time frame: After stimulation (15 mins post)

07

Study locations

1 of 2 sites recruiting
  • Hong Kong Polytechnic University
    Hong Kong, Hong Kong
    Recruiting
  • The Hong Kong Polytechnic University
    Hong Kong, Hong Kong
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431749
Lead sponsor
The Hong Kong Polytechnic University
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Jul 15, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Aug 24, 2026

Study contacts

JIAQI JACK Zhang, PhD
Contact
jack-jiaqi.zhang@polyu.edu.hk
27666696

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion